Equipoise in the Enhanced Supression of the Platelet IIb/IIIa Receptor with Integrilin Trial (ESPRIT): A critical appraisal

Clinical Trials

Volumn 2, Issue 3, 2005, Pages 233-241

  Mann, Howard ^a   London, Alex John ^b   Mann, Jeffrey ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

^c 1A71 University Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMED CONSENT; MEDICAL INFORMATION; METHODOLOGY; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESEARCH ETHICS; REVIEW; UNCERTAINTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATTITUDE OF HEALTH PERSONNEL; CLINICAL TRIALS DATA MONITORING COMMITTEES; COSTS AND COST ANALYSIS; ETHICS, RESEARCH; HUMANS; MULTICENTER STUDIES; PATIENT SELECTION; PEPTIDES; PHYSICIANS; PLACEBOS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SOCIAL RESPONSIBILITY; STENTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 21344470177     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1191/1740774505cn086oa     Document Type: Review

References (30)

1. O'Shea JC, Hafley GE, Greenberg S et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001; 285: 2468-73.
2. O'Shea JC, Tcheng JE. Eptifibatide in percutaneous coronary intervention: the ESPRIT trial results. Curr Interv Cardiol Rep 2001; 3: 62-68.
3. Tcheng JE, Madan M, O'Shea JC et al. Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycopiotein IIb/IIIa inhibition in coronary intervention. J Interv Cardiol 2003; 16: 97-105.
4. Sackett DL. Uncertainty about clinical equipoise. There is another exchange on equipoise and uncertainty. BMJ 2001; 322: 795-96.
5. Freedman B. Equipoise and the ethics of clinical research. New England Journal of Medicine 1987; 317: 141-45.
6. Djulbegovic B. Acknowledgment about uncertainty: a fundamental means to ensure scientific and ethical validity in research. Curr Oncol Rep 2001; 3: 389-95.
7. Mann H, Djulbegovic B. Why comparisons must address genuine uncertainties. James Lind Library, www. jameslindlibrary.org. (accessed 22 March 2005).
8. Mann H, Djulbegovic B. Choosing a control intervention for a randomised clinical trial. BMC Med Res Methodol 2003; 3: 7.
9. Winslow R. A type of heart drug wins wide use owing to small firm's efforts. Wall Street Journal. New York, 2000; 17 November Section A, Page 7.
10. London AJ. The ambiguity and the exigency: clarifying 'standard of care' arguments in international research. J Med Philos 2000, 25: 379-97.
11. Ashcroft R. Equipoise, knowledge and ethics in clinical research and practice. Bioethics 1999; 13: 314-26.
12. Eisenberg MJ, Califf RM, Cohen EA et al. Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. Am J Cardiol 1997; 79: 867-72.
13. Davis D, Evans M, Jadad A et al. The case for knowledge translation: shortening the journey from evidence to effect. BMJ 2003; 327: 33-35.
14. Ferguson JJ. What have We learned from ESPRIT? What will we learn from TARGET? J Invasive Cardiol 2000; 12: 317-19.
15. Freedman B. A response to a purported ethical difficulty with randomized clinical trials involving cancer patients. J Clin Ethics 1992; 3: 231-34.
16. Freedman B. Placebo-controlled trials and the logic of clinical purpose. IRB 1990; 12: 1-6.
17. Herper M. Eli Lilly changing ReoPro pricing. Forbes New York, 19 February 2003; http://www.forbes.com/ 2003/02/19/cx_mh_0219reopro.html (accessed 23 March 2005).
18. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products: Points to consider on switching between superiority and non-inferiority. 17 July 2000; http://www.emea.eu.int/pdfs/ human/ewp/048299en (accessed 23 March 2005).
19. Emanuel E, Wendler D, Grady C What makes clinical research ethical? Journal of the American Medical Association 2000; 283: 2701-11.
20. Weijer C. The ethical analysis of risk. Journal of Law Medicine and Ethics 2000; 28: 344-61.
21. National Bioethics Advisory Commission. Ethical and policy issues in research involving human participants. Bethesda, Maryland, 2001; http://www.georgetown.edu research/nredbl/nbac/pubs.html (accessed 23 March 2005).
22. O'Shea JC, Tcheng JE. Drug company sponsorship and the declaration of helsinki. Lancet 2001; 357: 1448-49.
23. Marquis D: How to resolve an ethical dilemma concerning randomized clinical trials. New England Journal of Medicine 1999; 341: 691-93.
24. Edwards SJ, Lilford RJ, Hewison J. The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals. BMJ 1998; 317: 1209-12.
25. Lilford RJ. Ethics of clinical trials from a bayesian and decision analytic perspective: whose equipoise is it anyway? BMJ 2003; 326: 980-81.
26. Veatch RM. Indifference of subjects: an alternative to equipoise in randomized clinical trials. Soc Philos Policy 2002; 19: 295-323.
27. Canadian Tri-Council Policy Statement. Section 7E - analysis and dissemination of the results of clinical trials. 2000; http://www.pre.ethics.gc. ca/english/policystatement/policystatement.cfm (accessed 23 March 2005).
28. Johnson N, Lilford RJ, Brazier W. At what level of collective equipoise does a clinical trial become ethical? J Med Ethics 1991; 17: 30-34.
29. Menikoff J. The hidden alternative: getting investigational treatments off-study. Lancet 2003; 361: 63-67.
30. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000; 133: 455-63.